VolitionRx Limited (NYSE American: VNRX) announced a significant advancement in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA from blood samples. The company's Capture-Seq(TM) platform has overcome a critical challenge in distinguishing cancer DNA from healthy cell-free DNA, which has limited the accuracy and reliability of liquid biopsy tests for years.
The breakthrough represents a major step forward in cancer diagnostics, as liquid biopsies offer a less invasive alternative to traditional tissue biopsies. Volition reported strong early validation results, including no false positives and successful detection across initial study cohorts. These findings support the technology's potential as a novel biomarker approach for both multi-cancer early detection and minimal residual disease monitoring.
The implications of this advancement are substantial for cancer patients and healthcare systems worldwide. Early detection remains crucial for improving cancer survival rates, and this technology could enable more accurate, accessible screening. The company estimates the combined total addressable market for these applications at approximately $36 billion, reflecting the significant unmet need in cancer diagnostics.
Volition is currently in active discussions with global diagnostic and liquid biopsy companies to accelerate development and commercialization of the platform. The company's research and development activities are centered in Belgium, with additional facilities in the United States and United Kingdom. For more information about Volition's work in epigenetics and disease detection, visit https://volition.com/.
The full press release detailing this breakthrough is available at https://ibn.fm/1ZqGi. This advancement comes at a critical time in cancer research, as the medical community continues to seek more effective methods for early detection and monitoring that can improve patient outcomes while reducing healthcare costs and patient discomfort associated with traditional diagnostic procedures.
